Relmada Therapeutics RLMD
NASDAQ RLMD
$3.60 -0.06 (-1.64%)
At close: Oct 2, 2026 · 4:00 PM EDT

Relmada Therapeutics (RLMD) Return on Equity [ROE] (2015 - 2026)

Updated

Relmada Therapeutics (RLMD) posted Return on Equity [ROE] of -28.80% for Q2 2026, up 326.77 percentage points from -355.57% a year earlier and up 9.48 percentage points from the prior quarter.

Analysis

Relmada Therapeutics (RLMD) Return on Equity [ROE] (2015 - 2026) Analysis & Trends

For FY2025, Relmada Therapeutics' Return on Equity [ROE] came in at -94.57%, up 38.39 percentage points from FY2024.

  • Annual Return on Equity [ROE] shows a five-year change of -39.58 percentage points (FY2020 to FY2025).
  • In prior years, Relmada Therapeutics' Return on Equity [ROE] was -132.96% in FY2024 (-45.67 pp), -87.29% in FY2023 (+5.19 pp), -92.49% in FY2022 (-12.38 pp) and -80.10% in FY2021 (-25.11 pp).
  • The Q2 2026 figure stands as the highest quarterly Return on Equity [ROE] since Q1 2020.
  • On a year-over-year basis, Return on Equity [ROE] has increased in each of the last three quarters, with an average year-over-year change of -21.18 percentage points over the last eight quarters.
  • The strongest year-over-year quarter for Return on Equity [ROE] in the past five years was Q2 2026, with a gain of 326.77 percentage points; the weakest was Q3 2025, with a drop of 281.70 percentage points.
  • According to Business Quant data, Return on Equity [ROE] for the three prior quarters was -38.28% (Q1 2026), -120.25% (Q4 2025) and -442.09% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 25.32%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 7.21%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 84.40%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 21.39%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 83.75%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -18.38%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 4.97%
10 Relmada Therapeutics 384.01 Mn 384.01 Mn - -28.80%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -28.80%
Mar 31, 2026 -38.28%
Dec 31, 2025 -120.25%
Sep 30, 2025 -442.09%
Jun 30, 2025 -355.57%
Mar 31, 2025 -262.95%
Dec 31, 2024 -193.30%
Sep 30, 2024 -160.40%
Jun 30, 2024 -129.89%
Mar 31, 2024 -118.85%
Dec 31, 2023 -105.92%
Sep 30, 2023 -105.33%
Jun 30, 2023 -108.99%
Mar 31, 2023 -112.75%
Dec 31, 2022 -105.12%
Sep 30, 2022 -86.31%
Jun 30, 2022 -78.89%
Mar 31, 2022 -67.64%
Dec 31, 2021 -89.48%
Sep 30, 2021 -132.65%
API Access

Relmada Therapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=RLMD&period=max&api_key=YOUR_API_KEY